Respiratory syncytial virus (RSV) is a major cause of respiratory illness, particularly dangerous for infants and the elderly. The virus can lead to bronchiolitis and pneumonia, requiring hospitalisation and intensive care in severe cases. The new vaccination programme is a proactive measure to mitigate these risks and enhance public health.
This is a UK-wide programme. The rollout will begin in September 2024 for England, Wales and Northern Ireland, and in August 2024 for Scotland.
These products will be used in new national immunisation programmes for infants and older adults following advice from the independent JCVI.
A national RSV vaccine programme protecting infants and elderly people will save lives in the UK.
- The UK is the first country in the world to offer a national vaccination programme that uses the same vaccine to protect both infants and older adults from RSV
- The vaccine will protect infants and older adults, easing winter pressures on the NHS
- Eligible people urged to take up offer when rollout begins in September 2024
The rollout of the vaccine will start from 2nd September 2024 at The Abingdon Surgery, it includes vaccine for pregnant women over 28 weeks to help protect their new born babies and a one-off campaign for people aged 75 to 79. These are the groups at the greatest risk from RSV, based on advice from the Joint Committee on Vaccination and Immunisation (JCVI).
People aged 75 to 79 years old are being sent texts messages inviting them to book their appointments for their RSV vaccination. Those turning 75 after this date will also receive an invitation from their GP once eligible.
Women that are at least 28 weeks pregnant will also receive a text inviting them to get the vaccine to protect their baby.
These vaccination programmes will save lives and significantly reduce the burden on the NHS during the challenging winter months.
For further information please click the link below:
National RSV vaccination programme announced – GOV.UK (www.gov.uk)